ArticleHuman gene therapy methods2012
Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device.
Article in Human gene therapy methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies.Veterinary and animal science · 2026Review
- Engineering of a wireless single capacitive discharge conductivity-clamped gene electrotransfer probe for naked nucleic acid therapeutics.APL bioengineering · 2026Article
- An engineered intradermal microneedle-array device enhances the cellular immune responses in a guinea pig model.Frontiers in immunology · 2026Article
- High-Throughput Capable Three-Dimensional Tissue Model for Quantification of Electroporation Thresholds.Journal of visualized experiments : JoVE · 2025Article
- Personalized immunization to optimize vaccine immunogenicity: exploring the multidimensional effects of host intrinsic factors, external intervention strategies, and the external environment.Frontiers in immunology · 2025Review
- Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation.Molecular therapy. Nucleic acids · 2023Article
- Lassa fever vaccine candidates: A scoping review of vaccine clinical trials.Tropical medicine & international health : TM & IH · 2023Article
- Neoantigen cancer vaccine augments anti-CTLA-4 efficacy.NPJ vaccines · 2022Article
- Fabrication and use of silicon hollow-needle arrays to achieve tissue nanotransfection in mouse tissue in vivo.Nature protocols · 2021Review
- Novel suction-based in vivo cutaneous DNA transfection platform.Science advances · 2021Article
- Structure-Activity Relationship of Mono-Ion Complexes for Plasmid DNA Delivery by Muscular Injection.Pharmaceutics · 2021Article
- Article
- Coalesced thermal and electrotransfer mediated delivery of plasmid DNA to the skin.Bioelectrochemistry (Amsterdam, Netherlands) · 2019Article
- Protective immunity by an engineered DNA vaccine for Mayaro virus.PLoS neglected tropical diseases · 2019Article
- Safe and efficient novel approach for non-invasive gene electrotransfer to skin.Scientific reports · 2018Article
- Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.Scientific reports · 2018Article
- Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques.Scientific reports · 2017Article
- Article
- Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin.Vaccine · 2017Article
- Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.Human gene therapy methods · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vivo electroporation (EP) is an efficient nonviral method for enhancing DNA vaccine delivery and immunogenicity in animals and humans. Intradermal delivery of DNA vaccines is an attractive strategy because of the immunocompetence of skin tissue. We have previously reported a minimally invasive surface intradermal EP (SEP) device for delivery of prophylactic DNA vaccines. Robust antibody responses were induced after vaccine delivery via surface EP in several tested animal models. Here we further investigated the optimal EP parameters for efficient delivery of DNA vaccines, with a specific emphasis on eliciting cellular immunity in addition to robust humoral responses. In a mouse model, using applied voltages of 10-100 V, transgene expression of green fluorescent protein and luciferase reporter genes increased significantly when voltages as low as 10 V were used as compared with DNA injection only. Tissue damage to skin was undetectable when voltages of 20 V and less were applied. However, inflammation and bruising became apparent at voltages above 40 V. Delivery of DNA vaccines encoding influenza virus H5 hemagglutinin (H5HA) and nucleoprotein (NP) of influenza H1N1 at applied voltages of 10-100 V elicited robust and sustained antibody responses. In addition, low-voltage (less than 20 V) EP elicited higher and more sustained cellular immune responses when compared with the higher voltage (above 20 V) EP groups after two immunizations. The data confirm that low-voltage EP, using the SEP device, is capable of efficient delivery of DNA vaccines into the skin, and establishes that these parameters are sufficient to elicit both robust and sustainable humoral as well as cellular immune responses without tissue damage. The SEP device, functioning within these parameters, may have important clinical applications for delivery of prophylactic DNA vaccines against diseases such as HIV infection, malaria, and tuberculosis that require both cellular and humoral immune responses for protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.